Oxford's R21 Malaria Vaccine: Single Shot, Global Impact

Oxford's R21/Matrix-M⢠vaccine, developed with the Serum Institute of India, offers a single-shot solution to malaria, a disease claiming over 600,000 lives yearly, mostly African children under five. This breakthrough could revolutionize global immunization efforts.
By eliminating the need for multiple doses, the R21 vaccine addresses challenges in regions with limited healthcare access. Experts highlight its potential to significantly reduce malaria mortality rates, emphasizing the importance of integrating this vaccine with existing preventive measures.
The Serum Institute plans to produce 100 million doses annually, pricing each under $4, making the vaccine both accessible and affordable for widespread distribution.